JP2018168170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018168170A5 JP2018168170A5 JP2018111869A JP2018111869A JP2018168170A5 JP 2018168170 A5 JP2018168170 A5 JP 2018168170A5 JP 2018111869 A JP2018111869 A JP 2018111869A JP 2018111869 A JP2018111869 A JP 2018111869A JP 2018168170 A5 JP2018168170 A5 JP 2018168170A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- composition
- alcohol
- compound
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 56
- 150000001875 compounds Chemical class 0.000 claims 33
- 150000002191 fatty alcohols Chemical class 0.000 claims 23
- 125000003700 epoxy group Chemical group 0.000 claims 19
- 102000001708 Protein Isoforms Human genes 0.000 claims 16
- 108010029485 Protein Isoforms Proteins 0.000 claims 16
- 102000003923 Protein Kinase C Human genes 0.000 claims 16
- 108090000315 Protein Kinase C Proteins 0.000 claims 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims 13
- 229930195729 fatty acid Natural products 0.000 claims 13
- 239000000194 fatty acid Substances 0.000 claims 13
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 12
- 229950011148 cyclopropane Drugs 0.000 claims 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 10
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 8
- 101150065749 Churc1 gene Proteins 0.000 claims 8
- 102100038239 Protein Churchill Human genes 0.000 claims 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 8
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 8
- -1 fatty acid esters Chemical class 0.000 claims 7
- 150000004665 fatty acids Chemical class 0.000 claims 7
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 6
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 6
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 6
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 6
- 230000004770 neurodegeneration Effects 0.000 claims 6
- 229940055577 oleyl alcohol Drugs 0.000 claims 6
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 6
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 claims 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 4
- IKYKEVDKGZYRMQ-PDBXOOCHSA-N (9Z,12Z,15Z)-octadecatrien-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCO IKYKEVDKGZYRMQ-PDBXOOCHSA-N 0.000 claims 4
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 4
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 claims 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 4
- 235000021342 arachidonic acid Nutrition 0.000 claims 4
- 229940114079 arachidonic acid Drugs 0.000 claims 4
- 229960004488 linolenic acid Drugs 0.000 claims 4
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 3
- CCPPLLJZDQAOHD-BEBBCNLGSA-N (-)-vernolic acid Chemical compound CCCCC[C@@H]1O[C@@H]1C\C=C/CCCCCCCC(O)=O CCPPLLJZDQAOHD-BEBBCNLGSA-N 0.000 claims 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- YHVNLORIIDPMPQ-RRABGKBLSA-N cyclopropane;(e)-octadec-9-enoic acid Chemical compound C1CC1.CCCCCCCC\C=C\CCCCCCCC(O)=O YHVNLORIIDPMPQ-RRABGKBLSA-N 0.000 claims 2
- VCDLWFYODNTQOT-UHFFFAOYSA-N docosahexaenoic acid methyl ester Natural products CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OC VCDLWFYODNTQOT-UHFFFAOYSA-N 0.000 claims 2
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims 2
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 claims 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims 2
- 229940098330 gamma linoleic acid Drugs 0.000 claims 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 2
- LUYYTKKXYNRVHQ-TYYHYDAASA-N methyl (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoate Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OC LUYYTKKXYNRVHQ-TYYHYDAASA-N 0.000 claims 2
- JTSVQVYMBXVLFI-IPASSIEDSA-N methyl (z)-11-[(2r,3s)-3-pentyloxiran-2-yl]undec-9-enoate Chemical compound CCCCC[C@@H]1O[C@@H]1C\C=C/CCCCCCCC(=O)OC JTSVQVYMBXVLFI-IPASSIEDSA-N 0.000 claims 2
- 150000004702 methyl esters Chemical class 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 2
- CCPPLLJZDQAOHD-UHFFFAOYSA-N vernolic acid Natural products CCCCCC1OC1CC=CCCCCCCCC(O)=O CCPPLLJZDQAOHD-UHFFFAOYSA-N 0.000 claims 2
- DVWSXZIHSUZZKJ-UHFFFAOYSA-N 18:3n-3 Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OC DVWSXZIHSUZZKJ-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- DVWSXZIHSUZZKJ-YSTUJMKBSA-N methyl linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OC DVWSXZIHSUZZKJ-YSTUJMKBSA-N 0.000 claims 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8417208P | 2008-07-28 | 2008-07-28 | |
| US61/084,172 | 2008-07-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016051212A Division JP6449186B2 (ja) | 2008-07-28 | 2016-03-15 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018168170A JP2018168170A (ja) | 2018-11-01 |
| JP2018168170A5 true JP2018168170A5 (enExample) | 2019-03-14 |
Family
ID=41136734
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521235A Expired - Fee Related JP5653917B2 (ja) | 2008-07-28 | 2009-07-28 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2014182597A Pending JP2015042643A (ja) | 2008-07-28 | 2014-09-08 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2016051212A Expired - Fee Related JP6449186B2 (ja) | 2008-07-28 | 2016-03-15 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2018111869A Pending JP2018168170A (ja) | 2008-07-28 | 2018-06-12 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521235A Expired - Fee Related JP5653917B2 (ja) | 2008-07-28 | 2009-07-28 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2014182597A Pending JP2015042643A (ja) | 2008-07-28 | 2014-09-08 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2016051212A Expired - Fee Related JP6449186B2 (ja) | 2008-07-28 | 2016-03-15 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US8163800B2 (enExample) |
| EP (3) | EP3403650A3 (enExample) |
| JP (4) | JP5653917B2 (enExample) |
| CA (2) | CA2731171C (enExample) |
| ES (1) | ES2683021T3 (enExample) |
| WO (1) | WO2010014585A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090030055A1 (en) * | 2002-07-02 | 2009-01-29 | Thomas Nelson | PKC activation as a means for enhancing sAPPALPHA secretion and improving cognition using bryostatin type compounds |
| ES2683021T3 (es) | 2008-07-28 | 2018-09-24 | Blanchette Rockefeller Neurosciences Institute | Compuestos activadores de la PKC para el tratamiento de enfermedades neurodegenerativas |
| AU2010313249B2 (en) | 2009-10-30 | 2016-05-19 | Biojiva Llc | Alleviating oxidative stress disorders with PUFA derivatives |
| JP5902103B2 (ja) * | 2010-02-22 | 2016-04-13 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | プロテインキナーゼｃイプシロン（ｐｋｃ−イプシロン）タンパク質レベルの、アルツハイマー病に特異的な変化 |
| JP6446624B2 (ja) * | 2010-07-08 | 2019-01-09 | アルコン、ダニエル・エル． | 脳卒中の治療法におけるｐｋｃ活性化因子および抗凝血剤 |
| CA2808660A1 (en) | 2010-08-19 | 2012-02-23 | Blanchette Rockefeller Neurosciences Institute | Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators |
| WO2012148929A2 (en) | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Disorders implicating pufa oxidation |
| JP6093756B2 (ja) * | 2011-04-26 | 2017-03-08 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | 損なわれたエネルギー処理障害およびミトコンドリア欠損症 |
| AU2012249917B2 (en) | 2011-04-26 | 2017-06-15 | Biojiva Llc | Neurodegenerative disorders and muscle diseases implicating PUFAs |
| WO2012148930A2 (en) | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Oxidative retinal diseases |
| US20140235496A1 (en) | 2011-10-05 | 2014-08-21 | Blanchette Rockefeller Neurosciences Drive | Stimulus-elicited genomic profile markers of a neurodegenerative condition |
| WO2013071281A1 (en) | 2011-11-13 | 2013-05-16 | Blanchette Rockefeller Neurosciences Institute | Esters of dcpla and methods of treatment using the same |
| EP2776018B1 (en) | 2011-11-13 | 2021-08-25 | Cognitive Research Enterprises, Inc. | Pkc activators and combinations thereof |
| WO2014126191A1 (ja) * | 2013-02-15 | 2014-08-21 | 株式会社西崎創薬研究所 | シクロプロパン環を有する不飽和脂肪酸誘導体を含むリン脂質化合物 |
| US20160025704A1 (en) * | 2013-03-15 | 2016-01-28 | Daniel L. Alkon | Methods for identifying neuroprotective pkc activators |
| EP4101835A1 (en) * | 2013-10-18 | 2022-12-14 | Blanchette Rockefeller Neurosciences Institute | 18f-substituted esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases |
| US20170172978A1 (en) | 2014-04-18 | 2017-06-22 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of lipid storage disorders |
| US9413754B2 (en) | 2014-12-23 | 2016-08-09 | Airwatch Llc | Authenticator device facilitating file security |
| EP3294290A1 (en) | 2015-05-11 | 2018-03-21 | Alkon, Daniel, L. | Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele |
| US20180256537A1 (en) | 2015-09-23 | 2018-09-13 | Tapan K. Khan | Methods for survival and rejuvenation of dermal fibroblasts using pkc activators |
| WO2017062924A1 (en) | 2015-10-08 | 2017-04-13 | Alkon Daniel L | Dosing regimens of pkc activators |
| AU2016361227B2 (en) | 2015-11-23 | 2021-06-10 | Biojiva Llc | Site-specific isotopic labeling of 1, 4-diene systems |
| JP6912072B2 (ja) * | 2016-12-14 | 2021-07-28 | 国立大学法人山口大学 | 前頭側頭型認知症の予防又は治療用医薬 |
| WO2018187647A1 (en) | 2017-04-06 | 2018-10-11 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of neurological diseases, disorders, or conditions |
| US20190350898A1 (en) * | 2018-05-18 | 2019-11-21 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of alzheimer's disease |
| US20220023255A1 (en) * | 2018-12-07 | 2022-01-27 | The Johns Hopkins University | Methods, compositions and kits for treating multiple sclerosis and other disorders |
| US11779910B2 (en) | 2020-02-21 | 2023-10-10 | Biojiva Llc | Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof |
| US20220133687A1 (en) * | 2020-11-02 | 2022-05-05 | Synaptogenix, Inc. | Methods of treating and preventing neurodegenerative diseases with hgf activating compounds |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
| EP4288047A4 (en) * | 2021-02-08 | 2024-12-11 | Synaptogenix, Inc. | Treatment of multiple sclerosis using pkc activators |
| EP4288046A4 (en) * | 2021-02-08 | 2024-12-11 | Synaptogenix, Inc. | TREATMENT OF OPTIC NERVE INFECTION WITH PKC ACTIVATORS |
| US20250345400A1 (en) * | 2022-05-18 | 2025-11-13 | Virginia Commonwealth University | Methods for treatment of cognitive impairment in cirrhosis patients |
| WO2025056602A1 (en) | 2023-09-11 | 2025-03-20 | Elastin Biosciences Ltd. | Pharmaceutical compositions and use thereof in treatment of conditions and diseases related to elastin deficiency and/or aging |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080784A (en) | 1986-06-11 | 2000-06-27 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators N |
| US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| US5242932A (en) | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| JPH06279311A (ja) | 1993-03-26 | 1994-10-04 | Sagami Chem Res Center | プロテインキナーゼｃアイソザイムの活性化剤 |
| US20030108956A1 (en) | 1993-05-03 | 2003-06-12 | Alkon Daniel L. | Cell tests for Alzheimer's disease |
| US6107050A (en) | 1993-05-03 | 2000-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic test for alzheimers disease |
| US5976816A (en) | 1993-05-03 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Cell tests for alzheimer's disease |
| US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| US5863902A (en) | 1995-01-06 | 1999-01-26 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
| US6303567B1 (en) | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US6001580A (en) | 1995-03-28 | 1999-12-14 | Takeda Chemical Industries, Inc. | Method for assaying ERK2 map kinase |
| US6277826B1 (en) | 1996-08-27 | 2001-08-21 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| WO1997032020A2 (en) | 1996-02-29 | 1997-09-04 | Mount Sinai Hospital Corporation | Shc proteins |
| JPH1090263A (ja) | 1996-07-25 | 1998-04-10 | Mclean Hospital Corp:The | アルツハイマー病の診断のためのｅｒｋ−１およびｅｒｋ−２の利用 |
| AU5994099A (en) | 1998-10-01 | 2000-04-26 | Urmas Arumae | A novel ret-independent signaling pathway for gdnf |
| AU5150300A (en) | 1999-05-19 | 2000-12-05 | Mitokor | Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| EP1224463A2 (en) | 1999-10-08 | 2002-07-24 | Superarray, Inc. | Compositions and methods for detecting protein modification and enzymatic activity |
| US20030165481A1 (en) | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| JP2003527604A (ja) | 2000-03-10 | 2003-09-16 | ワシントン・ユニバーシティ | 個々の細胞の標識方法 |
| EP1265849B1 (en) | 2000-03-23 | 2006-10-25 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
| US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
| JP2004508289A (ja) | 2000-04-03 | 2004-03-18 | デュポン ファーマシューティカルズ カンパニー | Ａβタンパク質産生の阻害剤としての環状ラクタム |
| EP1289966A1 (en) | 2000-04-11 | 2003-03-12 | Bristol-Myers Squibb Pharma Company | SUBSTITUTED LACTAMS AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION |
| JP2004502664A (ja) | 2000-06-30 | 2004-01-29 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病処置用化合物 |
| CA2417744A1 (en) | 2000-07-31 | 2002-02-07 | The Regents Of The University Of California | Model for alzheimer's disease and other neurodegenerative diseases |
| ATE330950T1 (de) | 2000-12-13 | 2006-07-15 | Wyeth Corp | Heterocyclische sulfonamide als inhibitoren der beta-amyloid-produktion |
| AUPR215700A0 (en) * | 2000-12-19 | 2001-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Carboxylic acid compound having cyclopropane ring |
| EP1390404A2 (en) | 2000-12-21 | 2004-02-25 | Novartis AG | Interleukin-1 related gene and protein |
| US20040086905A1 (en) | 2001-02-06 | 2004-05-06 | Debopriya Das | Lipid-associated molecules |
| JP4024554B2 (ja) | 2001-02-27 | 2007-12-19 | 松下電器産業株式会社 | 燃料電池発電システム |
| DE60226429D1 (de) | 2001-02-27 | 2008-06-19 | Brni Neurosciences Inst | Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung |
| US6874208B2 (en) | 2001-03-14 | 2005-04-05 | Autoliv Asp, Inc. | Anchoring attachment apparatus |
| EP1401452A1 (en) | 2001-06-27 | 2004-03-31 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamine derivatives useful in the treatment of alzheimer's disease |
| US20040014678A1 (en) | 2001-08-08 | 2004-01-22 | Antonella Favit | Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway |
| WO2004083241A2 (en) | 2003-03-19 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Btc-interacting proteins and use thereof |
| WO2006050475A2 (en) | 2004-11-03 | 2006-05-11 | Brigham And Women's Hospital, Inc. | Identification of dysregulated genes in patients with neurological diseases |
| CN101061237A (zh) | 2004-11-15 | 2007-10-24 | 布朗歇特洛克菲勒神经科学研究所 | 磷酸酶2a(pp2a)异常用于诊断与治疗阿耳茨海默病 |
| US8686177B2 (en) * | 2008-03-03 | 2014-04-01 | Rxbio, Inc. | LPA receptor agonists and antagonists |
| US20090182021A1 (en) | 2005-08-03 | 2009-07-16 | Nanternet Philippe G | Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease |
| WO2007044094A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| US20090029873A1 (en) | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
| US7595167B2 (en) | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
| WO2007043998A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio |
| WO2007047029A2 (en) | 2005-10-11 | 2007-04-26 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| CA2655126A1 (en) | 2006-06-21 | 2007-12-27 | Lexicor Medical Technology, Llc | Systems and methods for analyzing and assessing dementia and dementia-type disorders |
| JP2008143819A (ja) * | 2006-12-08 | 2008-06-26 | Tomoyuki Nishizaki | 酸化ストレス誘導細胞死の抑制剤 |
| WO2008100449A2 (en) | 2007-02-09 | 2008-08-21 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| US20100209914A1 (en) | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| ES2683021T3 (es) | 2008-07-28 | 2018-09-24 | Blanchette Rockefeller Neurosciences Institute | Compuestos activadores de la PKC para el tratamiento de enfermedades neurodegenerativas |
-
2009
- 2009-07-28 ES ES09790874.3T patent/ES2683021T3/es active Active
- 2009-07-28 WO PCT/US2009/051927 patent/WO2010014585A1/en not_active Ceased
- 2009-07-28 EP EP18172435.2A patent/EP3403650A3/en not_active Withdrawn
- 2009-07-28 EP EP09790874.3A patent/EP2328572B1/en not_active Not-in-force
- 2009-07-28 EP EP19189948.3A patent/EP3586839A1/en not_active Withdrawn
- 2009-07-28 US US12/510,681 patent/US8163800B2/en active Active
- 2009-07-28 JP JP2011521235A patent/JP5653917B2/ja not_active Expired - Fee Related
- 2009-07-28 CA CA2731171A patent/CA2731171C/en not_active Expired - Fee Related
- 2009-07-28 CA CA2941035A patent/CA2941035A1/en not_active Abandoned
-
2012
- 2012-02-21 US US13/401,459 patent/US9119825B2/en active Active
-
2014
- 2014-09-08 JP JP2014182597A patent/JP2015042643A/ja active Pending
-
2015
- 2015-07-20 US US14/803,762 patent/US10323011B2/en active Active
-
2016
- 2016-03-15 JP JP2016051212A patent/JP6449186B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-12 JP JP2018111869A patent/JP2018168170A/ja active Pending
-
2019
- 2019-05-01 US US16/400,132 patent/US10696644B2/en active Active
-
2020
- 2020-06-17 US US16/903,551 patent/US11390596B2/en active Active
-
2022
- 2022-07-06 US US17/858,204 patent/US11820745B2/en active Active
-
2023
- 2023-10-02 US US18/375,745 patent/US20240025870A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018168170A5 (enExample) | ||
| JP2011529503A5 (enExample) | ||
| Yeung et al. | The expansive role of oxylipins on platelet biology | |
| Darwesh et al. | Insights into the cardioprotective properties of n-3 PUFAs against ischemic heart disease via modulation of the innate immune system | |
| JP2020500193A5 (enExample) | ||
| Poorani et al. | COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance | |
| CL2021000645A1 (es) | Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto. | |
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| JP2014512351A5 (enExample) | ||
| JP2010196060A5 (enExample) | ||
| Lee | Resolvins as new fascinating drug candidates for inflammatory diseases | |
| JP2016538254A5 (enExample) | ||
| Auvin | Fatty acid oxidation and epilepsy | |
| JP2017526623A5 (enExample) | ||
| JP2013538817A5 (enExample) | ||
| RU2019110681A (ru) | Фармацевтическая композиция | |
| CN106795452A (zh) | 含有二十碳五烯酸烷基酯的组合物及其制造方法 | |
| UA111967C2 (uk) | Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання | |
| JP2016501248A5 (enExample) | ||
| ES2528012T3 (es) | Derivados de N-acil aminoácidos para el tratamiento de trastornos de la piel como la celulitis | |
| Moriyama et al. | Qualitative and quantitative effects of fatty acids involved in heart diseases | |
| JP2012513380A5 (enExample) | ||
| JP2016523826A5 (enExample) | ||
| JP2014114256A5 (enExample) | ||
| Wang et al. | Omega-6 polyunsaturated fatty acids and their metabolites: a potential targeted therapy for pulmonary hypertension |